ancotil 2,5 g/250 ml raztopina za infundiranje
lenis d.o.o. - raztopina za infundiranje - flucitozin
ancotil infuzija
raztopina za infundiranje - flucitozin
capecitabine sun
sun pharmaceutical industries europe b.v. - kapecitabin - stomach neoplasms; breast neoplasms; colonic neoplasms; colorectal neoplasms - kapecitabin - kapecitabin je indiciran za adjuvantno zdravljenje bolnikov po operaciji stopnje iii (dukes 'stadij c) raka debelega črevesa. capecitabine je primerna za zdravljenje metastatskega raka debelega črevesa in danke. capecitabine je določen za prvo linijo zdravljenja naprednih raka želodca v kombinaciji z platinum, ki temelji režim. capecitabine v kombinaciji z docetaxel je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari citotoksična kemoterapija. predhodno zdravljenje bi moralo vključiti antraciklin. capecitabine je prikazano tudi kot monotherapy za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari taxanes in anthracycline-ki vsebujejo kemoterapijo režim ali za koga še anthracycline zdravljenje ni navedeno.
tremfya
janssen-cilag international nv - guselkumab - psoriaza - imunosupresivi - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriatični arthritiscosentyx, samostojno ali v kombinaciji z metotreksatom (mtx), je primerna za zdravljenje aktivnega psoriatičnega artritisa pri odraslih bolnikih, kadar je odgovor na prejšnje bolezni spreminjanje anti revmatičnih drog (dmard) terapija je bila neustrezna. aksialni spondyloarthritis (axspa)ankilozirajoči spondilitis (kot, radiografski osno spondyloarthritis)cosentyx je primerna za zdravljenje aktivnega ankilozirajoči spondilitis pri odraslih, ki so se odzvali neustrezno konvencionalne terapije. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
emtricitabin/dizoproksiltenofovirat teva 200 mg/245 mg filmsko obložene tablete
teva b.v. - emtricitabin; dizoproksiltenofovirat - filmsko obložena tableta - emtricitabin 200 mg / 1 tableta dizoproksiltenofovirat245 mg / 1 tableta; dizoproksiltenofovirat 245 mg / 1 tableta - dizoproksiltenofovirat in emtricitabin
emtenovo 200 mg/245 mg filmsko obložene tablete
tad pharma gmbh - emtricitabin, tenofovir - filmsko obložena tableta - emtricitabin 200 mg / 1 tableta; tenofovir 136 mg / 1 tableta - dizoproksiltenofovirat in emtricitabin
emtricitabin/dizoproksiltenofovirat accordpharma 200 mg/245 mg filmsko obložene tablete
emtricitabin; tenofovir - filmsko obložena tableta - emtricitabin 200 mg / 1 tableta tenofovir136 mg / 1 tableta; tenofovir 136 mg / 1 tableta - dizoproksiltenofovirat in emtricitabin
kyntheum
leo pharma a/s - brodalumab - psoriaza - imunosupresivi - kyntheum je indiciran za zdravljenje zmerne do hude psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.
omvoh
eli lilly nederland b.v. - mirikizumab - kolitis, ulcerativni - imunosupresivi - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.